Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover

Trial Profile

Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs ECCS 50 (Primary)
  • Indications Raynaud's disease; Scleroderma; Systemic scleroderma
  • Focus Registrational; Therapeutic Use
  • Acronyms STAR
  • Sponsors Cytori Therapeutics
  • Most Recent Events

    • 15 Feb 2018 According to a Cytori Therapeutics media release, the company is currently working with statisticians and study investigators in preparation for publication of these results in a peer-reviewed journal.
    • 15 Feb 2018 Results presented in a Cytori Therapeutics media release.
    • 15 Feb 2018 According to a Cytori Therapeutics media release, data were presented at the 5th Systemic Sclerosis World Congress in Bordeaux, France.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top